Personally I think this revision is enough to get me over the line. I'm going to vote a YES on this.
For several reasons:
1) Loss of confidence in the current BOD (they are not looking after SH best interests nor does it seem like they're pushing to achieve true market penetration and revenue)
2) To recoup most of my initial investment (during these market conditions it's somewhat a blessing in disguise)
3) The pathway to commercialisation for RAP isn't looking too good although they like to dress it up as such.
I feel like being a LTH of RAP for all these years has not been worth it at all. Time to go.
- Forums
- ASX - By Stock
- Ann: Increased Scheme Consideration from Pfizer
Personally I think this revision is enough to get me over the...
-
- There are more pages in this discussion • 322 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAP (ASX) to my watchlist
|
|||||
Last
20.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $176.2M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
RAP (ASX) Chart |
Day chart unavailable
The Watchlist
LGP
LITTLE GREEN PHARMA LTD
Paul Long, CEO
Paul Long
CEO
Previous Video
Next Video
SPONSORED BY The Market Online